心血管疾病包括高血壓、動脈粥樣硬化、心肌梗死、心律失常、心肌病、瓣膜性心臟病、先天性心血和心力衰竭。鐵死亡（ferroptosis）屬于新的程序性細(xì)胞死亡方式，其病理特征是脂質(zhì)過氧化和鐵過載，心血管疾病中鐵死亡調(diào)控的主要途徑包括鐵代謝、脂質(zhì)代謝和氨基酸代謝等。近年來，中藥通過鐵死亡途徑發(fā)揮心血管疾病治療作用方面的研究愈來愈多，總結(jié)近5年中藥成分及復(fù)方制劑通過鐵死亡在心肌梗死、心力衰竭、心肌病、高血壓等心血管疾病的治療效果及相關(guān)作用通路，進(jìn)一步挖掘心血管疾病的治療靶點(diǎn)，以期為心血管疾病的治療及新藥研發(fā)提供新思路。

Cardiovascular diseases include hypertension, atherosclerosis, myocardial infarction, arrhythmia, cardiomyopathy, valvular Heart disease, congenital heart disease, and heart failure. Ferroptosis is a new mode of programmed cell death, which is characterized by lipid peroxidation and iron overload. The main regulatory pathways of iron death in cardiovascular diseases include iron metabolism, lipid metabolism and amino acid metabolism. In recent years, there have been more and more studies on the treatment of cardiovascular diseases by iron death of traditional Chinese medicine. This study aims to review the therapeutic effects and related pathways of traditional Chinese medicine components and compound preparations by iron death in cardiovascular diseases such as myocardial infarction, heart failure, cardiomyopathy and hypertension in the past five years, and further explore therapeutic targets for diseases. In order to provide new ideas for the treatment of cardiovascular diseases and the development of new drugs.

天津市制造業(yè)高質(zhì)量發(fā)展專項資金—天津天士力之驕藥業(yè)有限公司技術(shù)中心創(chuàng)新能力建設(shè)（ZZY20232088）